
| Top 5 Drug Type | Count |
|---|---|
| Proteolysis-targeting chimeras (PROTAC) | 40 |
| Small molecule drug | 30 |
| Polysaccharide | 7 |
| Chemical drugs | 5 |
| Herbal medicine | 2 |
Target |
Mechanism α5β1 stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date25 Jul 2006 |
Mechanism BK channel agonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date01 Jan 1993 |
Target |
Mechanism PARP1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Japan |
First Approval Date27 Oct 1961 |
Start Date01 Jul 2026 |
Sponsor / Collaborator |
Start Date28 Feb 2026 |
Sponsor / Collaborator |
Start Date24 Feb 2026 |
Sponsor / Collaborator |


| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Kakonein ( BK channel x L-type calcium channel x p53 ) | Reperfusion Injury More | Preclinical |
Pseudostellaria heterophylla polysaccharides ( CYP2E1 ) | Lower limb ischemia More | Preclinical |
Moutan cortex ( GnRHR ) | Breast Cancer More | Preclinical |
GDC-19 ( GPX4 ) | Neoplasms More | Preclinical |
STAT3 inhibitors(Zhejiang Chinese Medical University) ( STAT3 ) | Triple Negative Breast Cancer More | Preclinical |





